HepatitisBvirus (HBV) capsidassemblymodulators (CAMs) represent a promising therapeutic approach for the treatment of HBV infection. In this study, the hit compound (IC = 2.46 ± 0.33 μM) was identified by screening of an in-house compound library. And then novel potent benzimidazole derivatives were designed and synthesized as core assemblymodulators, and their antiviral effects were evaluated